RFK Jr. Cancels Key U.S. Health Panel Meeting Without Warning, Raising Concerns
FDA Publishes Full Texts of Response Letters to Drug Applications
The goal is to improve public understanding of the FDA decision-making process
NRTI Use Linked to Risk for Primary Open-Angle Glaucoma
Increased risk seen in adjusted analyses in association with nucleoside and nucleotide reverse transcriptase inhibitor use
Shorter-Form Messaging May Be Preferable for Trial Recruitment
Enrollment in DANFLU-2 trial was significantly more likely for those receiving single-page letter versus two-page letters
Health Care Expenditure Expected to Top GDP Growth 2024 to 2033
National health care expenditure growth expected to outpace GDP, resulting in a health share of GDP that reaches 20.3 percent by 2033
27.2 Million People of All Ages Uninsured in 2024 in the United States
Nonsignificant increase seen from 2023; 11.6 percent of adults aged 18 to 64 and 5.1 percent of children aged 0 to 17 were uninsured in 2024
NIH Stops Canceling Research Grants Following Court Ruling
Insurers Promise to Speed Up Delays in Health Care Approvals
FDA Approves Twice-Yearly Yeztugo for Preexposure Prophylaxis to Cut HIV Risk
Approval marks first and only twice-yearly option available in the United States for PrEP
FDA Offers Speedier Approvals to Drug Companies Aligning With ‘National Priorities’
Agency is offering vouchers to some drug manufacturers to shorten review time for final drug applications
